Selling a Pharmaceutical Services Business in the UK

Pharmaceutical services businesses in the UK command some of the highest EBITDA multiples in the mid-market — often in the range of 8x to 14x for well-positioned platforms. Buyers are active, competition between trade and private equity acquirers is genuine, and the regulatory complexity that makes these businesses hard to build is precisely what makes them attractive to acquire. If you are the owner of a CRO, a regulatory affairs consultancy, a clinical trial management business, or a specialist pharma manufacturer, the conditions for a sale are as favourable as they have been in a decade.

Contents

What counts as a pharmaceutical services business for sale purposes?

The pharma services sector is broader than most owners realise, and that breadth matters when you are thinking about positioning a sale. Buyers — particularly global CROs and PE-backed consolidators — are not just looking for direct competitors. They are looking for capability, accreditation, and client relationships they cannot easily replicate.

Businesses that typically attract strong acquisition interest include:

  • Contract Research Organisations (CROs) — clinical trial management, phase I–IV studies, biostatistics, data management
  • Regulatory affairs consultancies — MHRA submissions, EU market authorisation support, post-Brexit regulatory strategy
  • Pharmacovigilance and drug safety services — signal detection, adverse event reporting, QPPV outsourcing
  • Contract Development and Manufacturing Organisations (CDMOs) — specialist formulation, solid dose, sterile manufacture, API processing
  • Pharmaceutical logistics specialists — cold chain, clinical trial supply chain, GDP-compliant distribution
  • Medical writing and clinical affairs — CSRs, IND/IND-equivalent dossiers, label writing

If your business sits in any of these spaces, you are operating in a sector where acquirers have genuine strategic appetite and where UK assets are specifically sought after, in part because of the MHRA's post-Brexit independence and the UK's reputation as a leading clinical research environment.

What valuation multiples can you expect?

Multiples vary considerably depending on the nature of the revenue, the quality of client relationships, and the regulatory credentials of the business. The table below gives realistic ranges for UK mid-market businesses in this sector.

Sub-sectorTypical EBITDA Multiple RangeKey Valuation Drivers
CRO (clinical trial management)10x – 14xRepeat sponsor relationships, therapeutic focus, GCP certification
Regulatory affairs consultancy7x – 11xRetained clients, senior talent, EU/MHRA dual capability
Pharmacovigilance services9x – 13xRecurring contracts, QPPV-qualified staff, system infrastructure
CDMO (specialist manufacture)8x – 12xGMP accreditation, capacity utilisation, long-term supply agreements
Pharma logistics (GDP-compliant)6x – 9xCold chain infrastructure, clinical trial supply experience
Medical writing5x – 8xClient retention, therapeutic breadth, senior writer pipeline

These figures assume a business is EBITDA-positive, has meaningful accreditation, and is not overly reliant on a single client or individual. A business with £2m EBITDA and long-term frame agreements with two or three global pharma sponsors will attract a very different conversation to one with the same profit built on short-cycle project work.

What drives premium valuations in this sector?

Pharma services businesses trade at a premium to most sectors because of a combination of structural factors that genuinely limit competition. Understanding these helps you articulate the value of your business clearly to buyers.

Regulatory accreditations and compliance history MHRA inspections, GMP certification, GCP compliance, and a clean regulatory track record are not just operational requirements — they are barriers to entry that buyers pay for. A business with a long history of successful regulatory inspection outcomes is substantially more attractive than one that has remediation actions or gaps in its quality management system.

Client quality and concentration Revenue from top-20 global pharma companies carries more weight than revenue from early-stage biotechs, which may run out of funding between trials. Buyers will look hard at the mix. Ideally, you want no single client representing more than 20–25% of revenue, and a demonstrable record of clients returning for subsequent work.

Repeat and recurring revenue Project-based consulting revenue is the least valuable revenue type. Frame agreements, preferred supplier arrangements, and multi-year service contracts are significantly more attractive. If a significant proportion of your revenue renews annually without requiring competitive re-tendering, that will move the multiple.

Key personnel and scientific depth In a knowledge-intensive business, buyers want to know that the capability lives in the organisation, not just in the founder. This means documented processes, experienced second-tier management, and — critically — staff who are likely to stay post-acquisition. TUPE provisions apply to the transferred workforce, but retention of key scientific and regulatory personnel is usually addressed through specific deal structuring, including retention bonuses or earnout arrangements tied to individual performance.

Therapeutic focus and IP-adjacent positioning A CRO or regulatory consultancy with a defined therapeutic specialism — oncology, rare disease, CNS — is easier to value and more strategically useful to an acquirer than a generalist practice. Specialisation commands a premium.

Who are the buyers?

The buyer landscape for UK pharma services businesses is genuinely international and competitive.

Global and mid-market CROs — organisations looking to add UK capacity, therapeutic specialisms, or specific capabilities (e.g. early phase, real-world evidence). These buyers move quickly and understand the sector deeply. They will pay for genuine capability but will be rigorous in due diligence.

PE-backed pharma services consolidators — private equity has been active in building pharma services platforms for over a decade, both in Europe and globally. These buyers are highly acquisitive, move efficiently through process, and often bring significant operational resources post-acquisition. They are also comfortable with earnout structures and partial rollovers of equity.

Strategic trade acquirers from the US and Europe — US CROs and European pharma services groups looking to establish or deepen UK presence, particularly in the context of post-Brexit regulatory infrastructure. UK MHRA expertise is genuinely valued by overseas acquirers whose clients have UK submissions requirements.

Larger CDMOs — manufacturing acquirers looking to add formulation capability, sterile capacity, or niche technology platforms.

What does due diligence look like in pharma services?

Due diligence in this sector is more intensive than in most. Expect buyers to go deep in several areas that are relatively light-touch in other sectors.

  1. Regulatory compliance review — buyers will want access to inspection history, CAPA logs, quality management system documentation, and any regulatory correspondence with MHRA or EMA. A clean track record materially accelerates this.
  2. Client contract review — frame agreements, master service agreements, change of control clauses, and termination provisions will all be scrutinised. Change of control clauses that allow client exit on acquisition can be a significant deal risk.
  3. Personnel due diligence — key person dependencies, employment contract terms, restrictive covenants, and any pending employment disputes. TUPE implications for the workforce will be assessed.
  4. Financial quality of earnings — normalised EBITDA, project revenue recognition policies, deferred income treatment, and WIP accounting will be reviewed in detail. A QoE report from a reputable accountancy firm speeds this up.
  5. IP and data — any proprietary methods, software tools, databases, or analytical platforms need clear ownership documentation. Data governance and clinical data security will be reviewed carefully.
  6. Insurance and indemnity — professional indemnity cover, any historical claims, and run-off provisions.

Prepare for a process that takes longer than a standard trade sale. Six to nine months from mandate to completion is realistic, and twelve months is not unusual in complex regulatory environments.

How long does a pharma services sale take?

A structured sale process for a UK pharma services business typically follows this sequence:

  1. Preparation phase (2–4 months) — financial normalisation, regulatory documentation review, information memorandum, management presentation preparation
  2. Approach to market (4–8 weeks) — targeted outreach to strategic and PE buyers, NDAs, preliminary expressions of interest
  3. Indicative offers / HoTs (4–6 weeks) — management presentations, clarification Q&A, heads of terms negotiation
  4. Exclusivity and due diligence (8–14 weeks) — data room, legal and financial DD, regulatory DD, SPA negotiation
  5. Completion (2–4 weeks) — board approvals, CMA consideration (if thresholds met), funds transfer, Companies House filings

Total timeline: typically 9–14 months from appointment of advisers to completion.

If you are working through business valuation or comparing sector multiples, two guides on the Succession Group site will be directly useful. How to Value a Healthcare Business in the UK covers methodology and deal structures applicable across health-adjacent services sectors. EBITDA Multiples by Sector UK 2026 sets pharma services multiples in the context of the wider mid-market.

FAQ

What EBITDA multiple should I expect for a UK CRO sale? For a well-run CRO with recurring sponsor relationships, GCP accreditation, and a capable management team, 10x–14x EBITDA is a realistic range. Businesses that are heavily project-dependent or founder-reliant will sit at the lower end or below it.

Do I need MHRA accreditation to sell my pharma services business? It depends on the nature of the business. For manufacturing and clinical operations, GMP or GCP certification is typically essential — a buyer cannot operate a compliant business without it. For regulatory consultancy, accreditation matters less than the quality and track record of the team.

What is the biggest risk to a pharma services deal completing? Change of control clauses in client contracts are one of the most common deal risks. If your major clients can exit contracts on a change of ownership, buyers will price that risk heavily or seek contractual comfort before completion. Address this early.

Will a US buyer pay more than a UK or European trade buyer? Not necessarily, but US buyers often place particular strategic value on MHRA expertise and UK clinical trial infrastructure. If your business has strong post-Brexit regulatory capability, US acquirers may compete more aggressively than European peers.

Should I retain key scientific staff before going to market? Yes. Buyers will model key person risk carefully. If critical capability — particularly regulatory or clinical expertise — sits with one or two individuals, consider putting retention arrangements in place before a process begins. This protects value and signals organisational depth to buyers.

Does a pharma services business sale trigger any special HMRC or regulatory notifications? The sale itself is a standard share or asset transaction for HMRC purposes. Business Asset Disposal Relief (BADR) may apply to qualifying shareholders, currently at a 14% CGT rate on the first £1m of qualifying gains (rising to 18% from April 2026). For businesses with CMA-relevant turnover or market share, merger notification thresholds should be assessed. Separately, any regulated activities may require FCA or MHRA notification depending on the structure of the transaction.

This article contains general information only and does not constitute financial or tax advice. Every business sale is different. Speak to a qualified UK tax adviser about your specific situation before making any decisions.

Find out what your business could be worth. Use the free valuation calculator on the Succession Group website to get an indicative view of value based on your sector, revenue, and profitability. It takes under five minutes and gives you a grounded starting point for any exit conversation.